Clinical trial · Observational
An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer
A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of the Chinese Patients With T1 Non-small Cell Lung Cancer Complicated With Lymph Metastases
NCT03413956CI-TRIAL-00033013completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The real-world observational study was designed to explore the odd factors of lymph metastases in the patients with T1 non-small cell lung cancer, the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgeries | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- NSCLC patients with lymph metastases
- description
- Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
- interventionNames
- Procedure: Surgeries
Primary outcomes (1)
- measure
- Percentage of the patients with lymph metastases
- timeFrame
- 2015 - 2017
- description
- Percentages of the patients with lymph metastases categorised by patient demographic and tumor biological characteristics
Secondary outcomes (1)
- measure
- Percentages of N0/N1/N2/N3 patients
- timeFrame
- 2015 - 2017
- description
- Percentages of N0/N1/N2/N3 patients in the target population
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients who received surgeries from 2015 to 2017; * Pathologically diagnosed patients with T1 non-small cell lung cancer; Exclusion Criteria: \- Patients with tumor treatments (including chemotherapies, radiotherapies, biological therapies, intervention therapies)
References
Publications (0)
Data not yet available
No reference posted for this study.